Expertise in

conditions

Jurgen P. Debus

Heidelberg, BW, DE

Expertise in

conditions

Heidelberg, BW, DE

Overview

Jurgen Debus practices practicing medicine in Heidelberg, Germany.

Debus is highly rated in 34 conditions, according to our data. Their clinical expertise encompasses Adenoid Cystic Carcinoma, Glioma, Gliomatosis Cerebri, Mastectomy, and Prostatectomy.

They are actively involved in clinical research, co-authoring 824 peer reviewed articles and participating in 10 clinical trials.

Locations

Heidelberg, BW 69120, Germany

Other Locations

Salem, BW 69120, Germany

Munich, BY, Germany

Dresden, SN, Germany

Berlin, BE, Germany

BG Trauma Center Ludwigshafen, Ludwig Guttmann Strasse 13, Ludwigshafen Am Rhein, RP 67071, Germany

Frankfurt Am Main, HE, Germany

Oberschleissheim, BY 85765, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.

Enrollment Status: Active_not_recruiting

Publish Date: August 14, 2026

Intervention Type: Radiation, Drug

Study Drugs: Durvalumab, 5-Fluorouracil, Mitomycin C

Study Phase: Phase 2

An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: October 15, 2024

Intervention Type: Drug, Radiation

Study Phase: Phase 1

Observational Study on Biomarkers in Head and Neck Cancer

Enrollment Status: Completed

Publish Date: August 03, 2022

Intervention Type: Biological

Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux®

Enrollment Status: Completed

Publish Date: May 25, 2022

Intervention Type: Radiation, Drug

Study Drug: Erbitux®

Study Phase: Phase 4

Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional Fractionation

Enrollment Status: Completed

Publish Date: July 22, 2020

Intervention Type: Radiation

Study Phase: Not Applicable

Randomized Phase II Study Evaluating a Carbon Ion Boost Applied After Combined Radiochemotherapy With Temozolomide Versus a Proton Boost After Radiochemotherapy With Temozolomide in Patients With Primary Glioblastoma

Enrollment Status: Completed

Publish Date: April 03, 2020

Intervention Type: Radiation

Study Phase: Not Applicable

Clinical Phase I/II Trial to Investigate Preoperative Dose-Escalated Intensity-Modulated Radiation Therapy (IMRT) and Intraoperative Radiation Therapy (IORT) in Patients With Retroperitoneal Soft Tissue Sarcoma

Enrollment Status: Completed

Publish Date: April 03, 2020

Intervention Type: Radiation

Study Phase: Phase 1/Phase 2

Phase I/II Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma

Enrollment Status: Completed

Publish Date: January 10, 2020

Intervention Type: Radiation

Study Phase: Phase 1/Phase 2

Evaluation of Inter- and Intrafractional Motion of Liver Tumors Using Interstitial Markers and Implantable Electro-magnetic Radiotransmitters in the Context of Image-guided Radiotherapy (IGRT) - the ESMERALDA Trial

Enrollment Status: Withdrawn

Publish Date: May 17, 2018

Intervention Type: Behavioral

Study Phase: Not Applicable

Randomised Phase I/II Study to Evaluate Carbon Ion Radiotherapy Versus Fractionated Stereotactic Radiotherapy in Patients With Recurrent or Progressive Gliomas: The CINDERELLA Trial

Enrollment Status: Completed

Publish Date: May 17, 2018

Intervention Type: Radiation

Study Phase: Not Applicable

View 9 Less Clinical Trials

824 Total Publications

Corrigendum to "Human mesenchymal stromal cells maintain their stem cell traits after high-LET particle irradiation - Potential implications for particle radiotherapy and manned space missions" [Cancer Lett. (2022), 524, 172-181].

Journal: Cancer letters

Published: August 25, 2026

View All 824 Publications

Frequently Asked Questions about Jurgen P. Debus

Is Jurgen P. Debus a top-rated expert for Adenoid Cystic Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Jurgen P. Debus is classified as an Elite expert for Adenoid Cystic Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jurgen P. Debus participate in research or clinical trials?

Yes. Jurgen P. Debus has published 824 articles and abstracts on conditions like Adenoid Cystic Carcinoma. You can view a list of Jurgen P. Debus's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Debus's expertise for a condition

ConditionClose